HELLA Aktie 25974740 / DE000A13SX22
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
07.11.2025 07:00:03
|
EQS-News: FORVIA HELLA presents nine-month results 2025: Sales and profitability at previous year’s level
|
EQS-News: HELLA GmbH & Co. KGaA
/ Key word(s): 9 Month figures/9 Month figures
Lippstadt (Germany) 7 November 2025 FORVIA HELLA presents nine-month results 2025:
HELLA GmbH & Co. KGaA (“FORVIA HELLA”) today published its full financial results for the first nine months of fiscal year 2025 (1 January to 30 September 2025). As previously announced on 17 October 2025, Group-wide currency-adjusted sales increased slightly by 0.4 percent to €6.0 billion. Taking negative exchange rate effects into account, sales remained at €5.9 billion, therefore largely maintaining the level of the prior year. Over the same period, global light vehicle production rose by 3.8 percent, with Asia being the only region to growth. Operating income for the nine-month period amounted to €338 million (previous year: €344 million), keeping the operating income margin on prior-year level of 5.8 percent. Net cash flow improved significantly to €68 million (previous year: -€8 million), raising the ratio of net cash flow to sales to 1.2 percent (previous year: -0.1 percent).
“In the first nine months of the current fiscal year, we have continued to demonstrate strong resilience and adaptability. In a volatile industry environment, where only the Asian market is growing, we have managed to keep both sales and earnings stable and to significantly improve our net cash flow,” said Bernard Schäferbarthold, CEO of FORVIA HELLA. “We have therefore achieved very solid financial results overall under persistently challenging conditions. In this context, our various strategic and structural initiatives are paying off as well: not only by improving our global cost base and supporting efficient capital allocation, but above all by strengthening our position in an increasingly competitive market for the long term.” Electronics grows due to strong demand for radar sensors; market weakness and series phase-outs impact Lighting; sales in Lifecycle Solutions start to stabilize Group-wide sales in the first nine months of fiscal year 2025 were driven by the Electronics Business Group, which has increased sales by 5.6 percent year-on-year to €2.6 billion (previous year: €2.4 billion). The main driver was the global growth in radar business, resulting from both the launch of new customer projects this year as well as from the ramp-up of existing series production. In Europe and China, FORVIA HELLA’s electronics business benefited from higher demand for vehicle access systems. Additionally, in China, the low-voltage battery management systems business developed successfully. In contrast, sales in the Business Group Lighting declined by 8.5 percent to €2.7 billion (previous year: €3.0 billion). This was primarily due to a weak market environment, with declining vehicle production especially in Europe, as well as the phase-out of several high-volume customer projects in China and the Americas. Increased production volumes for certain headlamp and rear lamp projects in Europe and the Americas were able to only partially offset these effects. In the Business Group Lifecycle Solutions, sales decreased by 4.2 percent to €0.7 billion (previous year: €0.8 billion). The independent aftermarket business remained generally stable, supported by an expanded product offering in the Asian market. However, low investment activity among agricultural and construction machinery manufacturers negatively impacted the commercial vehicle business overall. Nevertheless, the stabilization observed in this Business Group during the second quarter continued further in the third quarter, resulting in slight sales growth for this selective period. Company outlook for the fiscal year 2025 confirmed CEO Bernard Schäferbarthold: “The financial results for the first three quarters are fully in line with our expectations. However, we expect that global light vehicle production will decline in the last quarter of the year. Additionally, the recently imposed restrictions within international trade present sizeable uncertainties to the international value chains. Therefore, we continuously monitor our global supply and logistics chains in order to implement mitigation measures in close collaboration with our customers and suppliers as effectively as possible.” FORVIA HELLA confirms its forecast for the fiscal year 2025, providing that the supply situation for semiconductors remains sufficiently secure and taking into account measures initiated to maintain supply chain stability. Accordingly, the Company continues to expect currency-adjusted sales of between around €7.6 and 8.0 billion, with an operating income margin in the range of between around 5.3 to 6.0 percent. Net cash flow is expected to be at least €200 million. Selected key financial figures in € millions or as a percentage of sales for the first nine months of the fiscal year (1 January to 30 September):
Note: The financial statement for the first nine months of the fiscal year 2025 is now available on the
07.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | HELLA GmbH & Co. KGaA |
| Rixbecker Str. 75 | |
| 59552 Lippstadt | |
| Germany | |
| Phone: | +49 (0)2941 38-7125 |
| Fax: | +49 (0)2941 38-6647 |
| E-mail: | Investor.Relations@hella.com |
| Internet: | www.hella.de/ir |
| ISIN: | DE000A13SX22, DE000A3E5DP8 |
| WKN: | A13SX2, A3E5DP |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Munich, Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 2225474 |
| End of News | EQS News Service |
|
|
2225474 07.11.2025 CET/CEST
Nachrichten zu HELLA GmbH & Co. KGaA
|
17:58 |
Börse Frankfurt in Grün: MDAX klettert zum Ende des Montagshandels (finanzen.ch) | |
|
15:58 |
Montagshandel in Frankfurt: MDAX steigt am Nachmittag (finanzen.ch) | |
|
09:28 |
XETRA-Handel: MDAX beginnt Sitzung im Plus (finanzen.ch) | |
|
07.11.25 |
Schwache Performance in Frankfurt: MDAX beendet den Freitagshandel in der Verlustzone (finanzen.ch) | |
|
07.11.25 |
Schwacher Handel in Frankfurt: MDAX nachmittags leichter (finanzen.ch) | |
|
07.11.25 |
Börse Frankfurt: MDAX am Freitagmittag im Minus (finanzen.ch) | |
|
07.11.25 |
EQS-News: FORVIA HELLA presents nine-month results 2025: Sales and profitability at previous year’s level (EQS Group) | |
|
07.11.25 |
EQS-News: FORVIA HELLA legt Neun-Monats-Ergebnisse 2025 vor: Umsatz und Ergebnis auf Vorjahresniveau (EQS Group) |
Analysen zu HELLA GmbH & Co. KGaA
| 13:16 | HELLA Hold | Deutsche Bank AG | |
| 02.10.25 | HELLA Hold | Deutsche Bank AG | |
| 28.07.25 | HELLA Hold | Deutsche Bank AG | |
| 27.06.25 | HELLA Hold | Deutsche Bank AG | |
| 03.04.25 | HELLA Hold | Deutsche Bank AG |
Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest
Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.
Schnell noch Plätze sichern!Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Shutdown-Ende in Sicht? US-Börsen mit Gewinnen -- SMI und DAX schlussendlich stärker -- Asiens Börsen letztlich in GrünDer heimische Aktienmarkt präsentierte sich am Montag mit Gewinnen. Anleger am deutschen Aktienmarkt wurden ebenso wieder mutiger. Die Wall Street beginnt die Woche fester. An den Märkten in Fernost ging es zum Wochenstart nach oben.


